$ALG

ALAMO GROUP INC (ALG): Results of Operations and Financial Condition

ALAMO GROUP INC (ALG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 3 ex991q22026.htm EX-99.1 Document For: Alamo Group Inc. Contact: Kevin Carter VP Finance, Strategy, and Investor Relations 830-372-9544 Financial Relations Board Joe Calabrese 212-827-3772 ALAMO GROUP ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 SEGUIN, Texas,

Original reporting
Published Aug 3, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 8:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ALG
Bullish
high confidence
Mentioned
$ALG
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ALGBullishMed
01

Why it matters

The filing provides fresh quarterly financial datapoints and a liquidity update (credit facility renewal) that can shift near-term expectations ahead of the earnings call.

02

Market read

Traders can update models using the disclosed Q2 sales, adjusted EPS/EBITDA, division performance, and liquidity terms, then reassess guidance risk for the Aug 4 call.

03

What to watch

Cash flow shows investing outflow of $171.6M for the first six months, so traders may scrutinize free-cash-flow conversion and any working-capital drag despite strong liquidity.

Relevance 7/10Novelty 8/10Timing: after-hours filing ahead of the Aug 4, 2026 earnings conference call

Background

This is an SEC Form 8-K with the company’s Q2 2026 results (Item 2.02) and related earnings-call logistics.

Company-level read

Ticker impact

$ALGBullishHigh confidence
Context

Alamo Group reported Q2 2026 net sales of $450.7M (+7.6% YoY) and adjusted EPS of $2.82 (+7.2% YoY), plus a renewed credit facility.

Expected impact

Likely modest positive bias into the Aug 4 earnings call, assuming no major outlook deterioration.

Evidence & confidence

The filing discloses multiple concrete operating and financial metrics (sales, adjusted EPS, adjusted EBITDA) and a balance-sheet/liquidity update (credit facility renewal with $602.5M committed capacity).

Market effects

Supports sentiment for industrial/vegetation equipment demand, especially where Industrial Equipment growth is cited as organic plus acquisition contribution.

No specific regional macro linkage beyond company end markets.

Limited; disclosure is company-specific with no stated global regulatory or supply-chain shock.

Counterpoint

Vegetation Management sales were nearly flat (+0.4% YoY), so consolidated growth may be more dependent on Industrial Equipment and acquisition contribution.

Key entities

  • Alamo Group Inc.

    Reported Q2 2026 results, renewed its credit facility in May 2026, and provided balance-sheet figures as of June 30, 2026.

  • Petersen

    Contributed to Industrial Equipment division sales growth following its acquisition earlier in 2026.

Related articles

$ALGMedAI 8/10

Alamo (NYSE:ALG) Delivers Impressive Q2 CY2026

Alamo Group (NYSE:ALG) reported Q2 CY2026 revenue of $450.7 million, up 7.6% year over year, beating Wall Street estimates by about 3%. Non-GAAP adjusted EPS was $2.82, up from $2.57, and 2.9% above consensus. Analysts expect full-year EPS to rise from $9.42 to $11.19 over the next 12 months.

$ALGMed

Alamo Group Q2 net sales rise 7.6 percent to $450.7 million

Alamo Group (ALG) reported Q2 2026 net sales of $450.7 million, up 7.6% from $419.1 million. Net income was $30.9 million and diluted EPS $2.55. Industrial Equipment sales rose 12.8% to $271.6 million, while Vegetation Management rose 0.4% to $179.1 million. Cash was $195.0 million, total debt $262.7 million.

$HCMMedAI 8/10

Why is HUTCHMED stock surging today?

HUTCHMED shares rose nearly 5% to HK$20.14 after the company reported positive topline results from its SAFFRON Phase III trial. The study of savolitinib (Orpathys) plus osimertinib (Tagrisso) in EGFR-mutant NSCLC met co-primary endpoints, improving progression-free and overall survival in patients with high MET overexpression or amplification after osimertinib progression. The move followed recent analyst target cuts.

$BSLMed

BlueScope profit soars 800 per cent as it pivots to shareholder returns

BlueScope reported FY2026 net profit after tax of $802m, up 857% from FY2025, with EBIT of $1.27b. The company attributed the jump to an impairment charge rolling off and said it is shifting from heavy investment to shareholder returns. It declared an unfranked final dividend of 65c and special dividend of 70c per share. Safety and blast furnace upgrade timelines were also discussed.